Skip to main content

Table 2 Cell cycle progression of NCI-H28 cells treated with ZOL and/or Ad-delE1B55

From: Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma

Time (hrs)

Treatment

Cell cycle distribution (% ± SE)

Sub-G1

G1

S

G2/M

>4 N

24

(−)

8.57 ± 0.34

57.61 ± 1.07

15.48 ± 0.53

16.96 ± 0.89

0.92 ± 0.21

 

Ad-LacZ

0.17 ± 0.02

58.59 ± 0.71

18.33 ± 0.19

22.24 ± 0.39

1.18 ± 0.17

 

Ad-delE1B55

0.25 ± 0.10

59.35 ± 0.68

20.28 ± 0.08

15.33 ± 0.38

5.45 ± 0.19

 

ZOL

0.16 ± 0.03

61.76 ± 0.64

25.71 ± 0.31

212.15 ± 0.48

0.89 ± 0.05

 

ZOL + Ad-LacZ

0.15 ± 0.03

67.62 ± 0.48

21.85 ± 0.35

9.87 ± 0.20

0.96 ± 0.07

 

ZOL + Ad-delE1B55

0.23 ± 0.03

65.45 ± 0.73

17.33 ± 0.21

14.21 ± 0.38

3.24 ± 0.24

48

(−)

2.79 ± 0.15

75.8 ± 0.13

9.30 ± 0.05

13.66 ± 0.20

0.93 ± 0.06

 

Ad-LacZ

0.24 ± 0.01

73.42 ± 0.15

9.22 ± 0.21

16.30 ± 0.20

1.08 ± 0.13

 

Ad-delE1B55

1.17 ± 0.05

1.70 ± 0.22

8.77 ± 0.22

36.84 ± 0.12

51.80 ± 0.28

 

ZOL

0.86 ± 0.10

58.00 ± 0.54

25.64 ± 0.15

15.28 ± 0.27

0.82 ± 0.11

 

ZOL + Ad-LacZ

0.70 ± 0.03

60.80 ± 0.20

25.40 ± 0.27

12.92 ± 0.28

0.77 ± 0.03

 

ZOL + Ad-delE1B55

1.44 ± 0.22

19.93 ± 1.20

47.98 ± 1.01a

1.28 ± 0.32

0.64 ± 0.37

72

(−)

1.06 ± 0.02

76.33 ± 0.64

9.26 ± 0.23

12.68 ± 0.28

0.92 ± 0.21

 

Ad-LacZ

0.51 ± 0.06

76.20 ± 0.37

8.68 ± 0.26

13.50 ± 0.46

1.41 ± 0.07

 

Ad-delE1B55

6.67 ± 0.17

2.15 ± 0.23

5.12 ± 0.49

27.45 ± 0.26

59.21 ± 0.85

 

ZOL

5.67 ± 0.23

59.46 ± 0.21

19.55 ± 0.57

14.86 ± 0.47

1.02 ± 0.07

 

ZOL + Ad-LacZ

6.07 ± 0.13

61.94 ± 0.30

16.93 ± 0.16

14.56 ± 0.12

0.97 ± 0.11

 

ZOL + Ad-delE1B55

8.56 ± 0.38a

7.77 ± 0.84

41.33 ± 1.20a

22.49 ± 0.42

20.77 ± 0.11

  1. Cells were treated with ZOL (80 μM) and/or either Ad-delE1B55 or Ad-LacZ (2 × 103 vp/cell) and cultured for 24–72 h. Cell cycle profiles were analyzed with flow cytometry. Averages with SEs are shown (n = 3)
  2. a p < 0.01; compared between ZOL + Ad-delE1B55-treated cells, and Ad-LacZ-, ZOL-, Ad-delE1B55-, ZOL + Ad-LacZ-treated cells